Press release
Xintela AB (publ)
556780-3480
2020-10-26

Xintela's stem cells show promising results in preclinical ARDS study

Lund, Sweden, 26 October 2020 - Xintela announces today that the company's selected human stem cells XSTEM® show a therapeutic effect in ARDS (Acute Respiratory Distress Syndrome) in an ongoing preclinical study in pigs. ARDS is a life-threatening lung complication that may affect severely ill covid-19 patients.

Xintela previously announced that XSTEM-ARDS is being evaluated in a well established preclinical pig model of ARDS and that Vinnova awarded a grant of SEK 1 million to fund the study. The preclinical study is being performed in collaboration with Professor Sandra Lindstedt and her team at the Cardio-thoracic surgery clinic, Skåne University Hospital in Lund and Lund University. The study involves twelve animals with the lung complication ARDS. Six animals receive intravenous treatment with XSTEM-ARDS and six control animals receive an injection without cells. During the study, various clinical parameters are monitored to measure lung and circulatory function and the health status of the animals. Blood and tissue samples are also collected and will be analyzed when the study is completed. Two animals remain to be treated before the final results can be compiled. The results so far show that XSTEM-ARDS had a positive therapeutic effect in all four animals that received stem cells. This positive effect is based on, among other things, improvement in the lungs' ability to oxygenate blood and stabilization of the blood circulatory system, compared to no improvement in the control animals, who remained in the life-threatening ARDS condition throughout the study.

"We have successfully completed the major part of the study and the results are very promising. In all animals treated with XSTEM-ARDS, we see a clear improvement in lung function and a reversal of the critical ARDS condition. For logistical reasons, it will take some time before we can complete the study, so we have chosen to report the current status and results thus far of this exciting study", says Xintela's CEO Evy Lundgren-Åkerlund.

"There is currently no effective treatment for ARDS. It is therefore encouraging to see the promising results with Xintela's stem cells in a model that is clinically similar to the life-threatening lung complication in ARDS patients. The results show that XSTEM-ARDS has the potential to improve the severe condition in ARDS patients, which can shorten intensive care time and reduce mortality", says Professor Sandra Lindstedt.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 26th of October, 2020.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in

Press release
Xintela AB (publ)
556780-3480
2020-10-26

Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.